GlassScriptPhysician profile
Kristin Miller
NPI 1003815283
$2,133.15
in general payments reported to CMS, 2019-2025
21 companies · $506 in 2025
The $506 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $151 · 2021: $360 · 2022: $356 · 2023: $360 · 2024: $209 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989 · Education: $86.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.98 |
| Education | $86.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $442.47 | 2019-2023 | |
| Exeltis, USA INC. | $385.94 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $295.07 | 2021-2025 | |
| Therapeuticsmd, INC. | $138.46 | 2019-2022 | |
| Exact Sciences Corporation | $108.15 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $105.10 | 2025 | |
| Pfizer INC. | $101.05 | 2019-2023 | |
| Astellas Pharma US INC | $100.79 | 2023-2024 | Veozah |
| Millicent US INC | $92.08 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Mylan Pharmaceuticals INC. | $86.09 | 2020-2022 | |
| Avion Pharmaceuticals | $66.13 | 2019-2023 | NP Thyroid 60 |
| Agile Therapeutics, INC. | $44.87 | 2021-2022 | |
| Hologic Sales and Service, LLC | $42.31 | 2025 | Myosure Tissue Removal Device, Novasure |
| Medtronic, INC. | $19.40 | 2024 | Truclear |
| Duchesnay USA Incorporated | $18.33 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17.01 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $16.54 | 2023 | Accrufer |
| Myovant Sciences INC. | $14.10 | 2022 | |
| Allergan, INC. | $13.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.86 | 2019 | |
| Boston Scientific Corporation | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.